Scientific Reference
Cagrilintide (AM833)
Evidence profile: Human Phase 3 evidence
Cagrilintide (AM833) is a long-acting, lipidated amylin analogue with activity at both amylin and calcitonin receptors. Its acylation gives an extended half-life suited to once-weekly administration in study protocols, and it has been investigated both alone and alongside GLP-1 receptor agonists in published metabolic research. Cagrilintide is not an approved medicine and remains investigational. Supplied strictly as a research compound for laboratory use.
Published Research
REDEFINE 1
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
Garvey WT et al. · The New England journal of medicine · 2025 · Clinical
PMID 40544433 — View on PubMedOnce-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
Lau DCW et al. · Lancet (London, England) · 2021 · Clinical
PMID 34798060 — View on PubMedEfficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial
Yamauchi T et al. · The lancet. Diabetes & endocrinology · 2026 · Clinical
PMID 42009015 — View on PubMedCagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
Rosenstock J et al. · Lancet (London, England) · 2026 · Clinical
PMID 42251856 — View on PubMedCagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study
Buse JB et al. · The lancet. Diabetes & endocrinology · 2026 · Clinical
PMID 42251859 — View on PubMedEfficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial
Loomba R et al. · The lancet. Gastroenterology & hepatology · 2026 · Clinical
PMID 42456707 — View on PubMed